ArticleAntimicrobial agents and chemotherapy2022
Pharmacokinetics and Pharmacodynamics of Clofazimine for Treatment of Cryptosporidiosis.
Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Examination of ELISA against PCR for assessing treatment efficacy against Cryptosporidium in a clinical trial context.PloS one · 2023Trial
- Genomic heterogeneity of NAD(P)H dehydrogenase predisposes Cryptosporidium to clofazimine resistance.Nature microbiology · 2026Article
- Nitazoxanide Exhibits Schistosomicidal Activity Against Schistosomula and Adult Schistosoma mansoni and Influences Praziquantel-Associated Outcomes.Acta parasitologica · 2026Article
- Phytoextracts Used in the Treatment of Cryptosporidiosis and Giardiasis: Current State.Acta parasitologica · 2026Review
- Widespread genomic heterogeneity at the type II NAD(P)H dehydrogenase locus predisposesbioRxiv : the preprint server for biology · 2025Article
- Molecular pathogenesis of Cryptosporidium and advancements in therapeutic interventions.Parasite (Paris, France) · 2025Review
- Exploration of innovative drug repurposing strategies for combating human protozoan diseases: Advances, challenges, and opportunities.Journal of pharmaceutical analysis · 2025Review
- Effects of Different Weak Small Organic Acids on Clofazimine Solubility in Aqueous Media.Pharmaceutics · 2024Article
- Therapeutic potential of platelet rich plasma against experimentalJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2024Article
- Clofazimine pharmacokinetics in HIV-infected adults with diarrhea: Implications of diarrheal disease on absorption of orally administered therapeutics.CPT: pharmacometrics & systems pharmacology · 2024Article
- Genomic and virulence analysis of in vitro cultured Cryptosporidium parvum.PLoS pathogens · 2024Article
- Structure-activity relationship of BMS906024 derivatives for Cryptosporidium parvum growth inhibition.Bioorganic & medicinal chemistry letters · 2023Article
- Clofazimine for the treatment of tuberculosis.Frontiers in pharmacology · 2023Review
- The Marine Compound Tartrolon E Targets the Asexual and Early Sexual Stages ofMicroorganisms · 2022Article
- Efficacy of clofazimine and nitazoxanide combination in treating intestinal cryptosporidiosis and enhancing intestinal cellular regeneration in immunocompromised mice.Food and waterborne parasitology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
Abstract
Infection with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.